Current Research
The Buffalo Institute of Medical Research is dedicated to actively supporting research.
Learn more about our ongoing clinical research studies:
PI:
Provost
Sponsor:
AstraZeneca
Brief Summary:
ACCT #601
Defining the Impact of Budesonide, Fluticasone Propionate and Fluticasone Furoate on the Alveolar Macrophage Immune Response to Community Acquired Pneumonia Pathogens in COPD (PT010) ESR-19-14563, D5980C00031
PI:
Berenson
Sponsor:
VA Merit
Brief Summary:
ACCT #608
Alveolar macrophage dysregulation in the pathogenesis of Gulf War respiratory illness
PI:
Dosluoglu
Sponsor:
Shape Memory Medical Inc. CRO:North American Science Associates, LLC (NAMSA)
Brief Summary:
ACCT #618
AAA Shape Trial- AAA-SHAPE Pivotal Randomized Controlled Trial and the potential to participate as the principal investigator for Buffalo VA Medical Center. This study involves a novel device composed of a shape memory polymer designed to promote abdominal aortic aneurysm sac healing and regression.
PI:
Puckett
Sponsor:
Piomic Medical Inc. CRO:North American Science Associates, LLC (NAMSA)
Brief Summary:
ACCT #620
Mavericks: Concurrent optical and magnetic stimulation (COMS) for treatment of refractory diabetic foot ulcer; a prospective randomized, sham-controlled, double-blinded, pivotal clinical trial
PI:
Dosluoglu
Sponsor:
TR Therapeutics Tissue Repair Ltd
Brief Summary:
ACCT #621
RE: Glucoprime ( from Tissue Repair for the treatment of Venous Leg Ulcers (VLUs). We will be conducting this study in the US
PI:
Mador
Sponsor:
AstraZeneca
Brief Summary:
ACCT #624
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease. EMBARK Study
PI:
Provost
Sponsor:
Sanofi
Brief Summary:
ACCT #625
Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) ECF16819-AERIFY-4 LTS18133
PI:
Rivero
Sponsor:
VA- CSP
Brief Summary:
ACCT #626
Impact of Colchicine on Peri-Operative Major Adverse Cardiovascular Events in Patients with Prior Coronary Revascularization The Peri-OPerative COlchicine to Reduce Negative events (POPCORN) Trial
PI:
Dosluoglu
Sponsor:
NERI
Brief Summary:
ACCT #627
BEST-CLI extension
PI:
Beehler
Sponsor:
NIH R34
Brief Summary:
ACCT #628
Enhancing Chronic Pain Care for Veterans: A Feasibility Trial of the Pain Coach Mobile Intervention
PI:
Hu
Sponsor:
UB
Brief Summary:
ACCT #629
The role of the extracellular adenosine pathway in the age-driven susceptibility to pulmonary infections
PI:
Provost
Sponsor:
Sanofi
Brief Summary:
Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study toevaluate the effi cacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33mAb) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD)
PI:
Mador
Sponsor:
Roche/Genentech
Brief Summary:
Chronic Obstructive Pulmonary Disease (COPD)
PI:
Dosluoglu
Sponsor:
Regeneron
Brief Summary:
A Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Factor XI Monoclonal Antibodies, in Patients with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease